Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00907179 · ClinicalTrials.gov registry record · Phase 1
Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by University of Pittsburgh.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00907179 is a Phase 1 study that was terminated before completion, run by University of Pittsburgh. The registered enrollment target is 12 participants.
The verdict
NCT00907179, a Phase 1 study, was terminated before completion, sponsored by University of Pittsburgh.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
LBH589 is a drug that may slow down the growth of cancer cells or kill cancer cells by blocking certain enzymes. LBH589 has shown effects against cancer in laboratory studies and in studies using animals; however, it is not known if this medicine will show the same activity in humans. As of May 2006, approximately 100 patients have received treatment with either an intravenous or capsule form of LBH589. Only the capsule form of LBH589 will be used in this study. In addition, information from other research studies and laboratory studies suggests that this study drug may help to treat lung cancer. The main goal during the Phase I portion of this research study is to find out the highest and safest dose of LBH589 that can be given in combination with pemetrexed in subjects with lung cancer without causing severe side effects. The main goal of the Phase II portion of this study is to find how the patient's lung cancer responds to the LBH589 in combination with pemetrexed. This study will also investigate how the patient's body processes the combination of LBH589 and pemetrexed. To determine this, the investigators will measure the amount of study drug in the patient's blood. This will be done with a series of blood tests, called pharmacokinetic (PK) tests. Other purposes of this study will be to determine the side effects of LBH589 in combination with pemetrexed and whether or not this combination is effective in treating your type of cancer.
Interventions
- DRUG Pemetrexed
- DRUG LBH 589
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-07 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00907179
The ClinicalTrials.gov registry entry for NCT00907179 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pemetrexed is the first listed.
NCT00907179 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00907179 about?
NCT00907179 is a clinical study titled "Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer". LBH589 is a drug that may slow down the growth of cancer cells or kill cancer cells by blocking certain enzymes. LBH589 has shown effects against cancer in laboratory studies and in studies using animals; however, it is not known if this medicine will show the same activity in humans. As of May 2006...
What is the current status of trial NCT00907179?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2009-07. Estimated completion is 2015-07.
What interventions are being tested in trial NCT00907179?
The interventions under investigation include: Pemetrexed (DRUG), LBH 589 (DRUG).
Who is sponsoring clinical trial NCT00907179?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.